Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, in accordance with Disclosure and Transparency Rule (DTR) 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details an increase in the notional allocation of GSK American Depositary Shares (ADSs) on March 13, 2015. This change resulted from the revaluation of the cash element of the notional investment held within the GSK 401K plan. The transaction occurred at a price of $46.37 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific director and connected person transactions described above.
Important Facts for Investors
- Transaction Date: March 13, 2015 (Notified March 16, 2015).
- Transaction Price: $46.37 per ADS.
- Director Transaction: Dr. M. M. Slaoui received an increase of 14 ADSs.
- Connected Person Transaction: Dr. K. Slaoui (connected to Dr. M. M. Slaoui) received an increase of 42 ADSs.
- Context: These increases were due to the revaluation of the cash element within the GSK 401K plan, not direct market purchases.